Hutchmed (China) Limited
Biopharmaceutical firm developing targeted therapies for cancer and immune diseases.
HCM | HKEX
Overview
Corporate Details
- ISIN(s):
- KYG4672N1198 (+1 more)
- LEI:
- 2138006X34YDQ6OBYE79
- Country:
- Hong Kong
- Address:
- LEVEL 18, THE METROPOLIS TOWER, KOWLOON
- Website:
- https://www.hutch-med.com/
- Sector:
- Manufacturing
Description
Hutchmed is a commercial-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapeutics and immunotherapies. The company operates a fully integrated platform, advancing a pipeline of novel drug candidates for the treatment of cancer and immunological diseases. Its research and development strategy focuses on creating highly selective and potent therapies engineered to improve drug exposure and reduce off-target toxicities. Hutchmed has multiple internally discovered medicines approved and marketed for various oncology and immunology indications, supported by a global commercialization infrastructure.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-12-31 08:00 |
Blocklisting Six Monthly Return
|
English | 30.2 KB | ||
| 2021-12-31 08:00 |
Total Voting Rights
|
English | 14.1 KB | ||
| 2021-12-20 08:00 |
HUTCHMED Included in FTSE Russell Indexes
|
English | 13.9 KB | ||
| 2021-12-15 10:45 |
Grant of Share Options and Awards under LTIP
|
English | 28.3 KB | ||
| 2021-12-14 08:00 |
HMPL-523 Clinical Data Presented at ASH
|
English | 25.8 KB | ||
| 2021-12-10 11:00 |
HUTCHMED Presents Data at ESMO Immuno-Oncology ‘21
|
English | 28.6 KB | ||
| 2021-12-06 08:00 |
HUTCHMED Completes Planned Enrollment of FRESCO-2
|
English | 28.9 KB | ||
| 2021-12-03 08:00 |
Updated NRDL to include ELUNATE and SULANDA
|
English | 25.2 KB | ||
| 2021-11-30 09:30 |
Total Voting Rights
|
English | 13.5 KB | ||
| 2021-11-24 08:00 |
HUTCHMED and AZ Initiate SACHI Phase 3 Trial
|
English | 42.2 KB | ||
| 2021-11-08 08:00 |
HUTCHMED to Present Clinical Data at ASH
|
English | 25.3 KB | ||
| 2021-11-01 08:00 |
HUTCHMED and AZ Initiate SAMETA Global P3 Trial
|
English | 35.2 KB | ||
| 2021-10-29 10:30 |
Total Voting Rights
|
English | 14.2 KB | ||
| 2021-10-28 08:00 |
HUTCHMED Initiates Phase III Trial of HMPL-523
|
English | 22.0 KB | ||
| 2021-10-20 10:30 |
Grant of Awards under Long Term Incentive Plan
|
English | 24.1 KB |
Automate Your Workflow. Get a real-time feed of all Hutchmed (China) Limited filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Hutchmed (China) Limited
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Hutchmed (China) Limited via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
